Navigation Links
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis
Date:11/14/2012

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- TissueGene, Inc. announced today that it has completed patient enrollment for a U.S. Phase II clinical trial of TG-C in patients suffering from severe osteoarthritis of the knee.  TG-C is a therapy that involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 to regenerate cartilage.

The randomized, double-blind, placebo-controlled study has been designed to evaluate the safety and efficacy of TG-C in patients with Grade 3 chronic degenerative joint disease (DJD) of the knee.  This multi-center study has been conducted at five hospitals and clinical research centers across the country specializing in orthopedics.  Patients have received an intra-articular injection of either TG-C or placebo to the damaged joint area.  Patients in this study are being followed for two years with the primary efficacy endpoint analysis being conducted once all patients have reached their one year follow-up.  In conjunction with this milestone, TissueGene's licensing partner, Kolon Life Science, Inc. has completed patient enrollment for a Phase IIb study of TG -C in Korea.  

"We are very pleased with the clinical progress of TG-C in both the US and Korea and look forward to reporting our Phase II data in 2013," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene.

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing novel regenerative therapies for the treatment of various orthopedic diseases.  TissueGene's proprietary technology employs a form of cell-mediated therapy to deliver therapeutic proteins to localized areas of damaged tissue.  The company is currently developing four product candidates for the regeneration of cartilage (TG-C), bone (TG-B), disc (TG-D), and nerve tissue (TG-N).  For more information, please visit http://www.TissueGene.com.

About Kolon Life Science, Inc.

Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary company of Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals.  Its pharmaceutical business division provides active pharmaceutical ingredients and pharmaceutical intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose.  For more information, please visit http://www.kolonls.co.kr.


'/>"/>
SOURCE TissueGene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
4. CryoLife Completes Acquisition of Hemosphere
5. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Ablative Solutions Completes $5.3M Series A Financing
10. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
11. Spine Pain Management, Inc. Completes $500,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... -- Memorial Hermann Health System has teamed up with Houston ... a one-of-a-kind experience to pediatric patients at Children,s ... 360-degree video and Google Cardboard, Howard was able to ... the patients and their families an unexpected, and energetically ... video . Memorial Hermann IRONMAN Sports ...
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... ... , ... When an Au Pair comes all the way around the world to ... and they are often worried things won’t go well. More often than not, however, they ... Pair of the Year winner’s all commented how their Au Pairs have become a part ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... ... , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 p.m. ... learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement actions ... takes time. , Take a close look at the warning letters the agency sent ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
Breaking Medicine News(10 mins):